Drugs for Bladder Cancer (Urothelial Carcinoma)

Table. Drugs Prescribed for Bladder Cancer (Urothelial Carcinoma)

• Drug name (generic name)
• Drug company
• Indications
• Patient support services

Drug name (generic name)
• Balversa (erdafitinib)
Drug company
• Janssen
Indication
• Treatment of locally advanced or metastatic bladder cancer that has a susceptible FGFR3 or FGFR2 genetic mutation and has progressed during or after chemotherapy
Patient support services
• Janssen CarePath Savings Program
  866-378-1910
  
  Johnson & Johnson Patient Assistance Foundation
  800-652-6227

Drug name (generic name)
• Bavencio (avelumab)
Drug company
• EMD Serono
Indications
• Treatment of locally advanced or metastatic bladder cancer that progressed during or after platinum-based chemotherapy or within 12 months of neoadjuvant or adjuvant platinum-based chemotherapy
  
  Maintenance treatment of locally advanced or metastatic bladder cancer that has not progressed with first-line platinumcontaining chemotherapy
Patient support services
• CoverOne Co-Pay Assistance Program
  844-826-8371
  
  CoverOne Patient Assistance Program
  844-826-8371

Drug name (generic name)
• Jelmyto (mitomycin)
Drug company
• UroGen Pharma
Indications
• Treatment of adults with low-grade upper tract urothelial cancer
Patient support services
• UroGen Support Copay Program
  855-535-6986
  
  UroGen Support Patient Assistance Program
  855-535-6986

Drug name (generic name)
• Keytruda (pembrolizumab)
Drug company
• Merck
Indications
• Treatment of patients with locally advanced or metastatic bladder cancer who are not eligible for platinum-containing therapy and whose tumors express PD- L1, as determined by an FDAapproved test
  
  Treatment of patients with locally advanced or metastatic urothelial carcinoma whose disease progressed during or after platinum-based chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy
  
  Treatment of patients with Bacillus Calmette-Guérin unresponsive, high-risk, non-muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors, who are ineligible for or have elected not to undergo cystectomy
Patient support services
• Merck Co-pay Assistance Program
  855-257-3932
  
  Merck Patient Assistance Program
  855-257-3932

Drug name (generic name)
• Opdivo (nivolumab)
Drug company
• Bristol Myers Squibb
Indications
• Treatment of locally advanced or metastatic bladder cancer that progressed during or after platinum-based chemotherapy or within 12 months of neoadjuvant or adjuvant platinum-based chemotherapy
  
  Adjuvant treatment of patients with bladder cancer who are at high risk of recurrence after undergoing radical resection (surgical removal) of the tumor
Patient support services
• BMS Oncology Co-Pay Assistance Program
  800-861-0048
  
  Bristol Myers Squibb Patient Assistance Foundation
  800-736-0003

Drug name (generic name)
• Padcev (enfortumab vedotin-ejfv) Injection
Drug company
• Astellas/Seagen
Indication
• Treatment of locally advanced or metastatic bladder cancer after treatment with a PD-1 or PD-L1 inhibitor, and a platinum-containing chemotherapy in the neoadjuvant or adjuvant, locally advanced or metastatic setting
Patient support services
• Padcev Copay Assistance Program
  888-402-0627
  
  Padcev Patient Assistance Program
  888-402-0627

Drug name (generic name)
• Tecentriq (atezolizumab)
Drug company
• Genentech
Indication
• Treatment of locally advanced or metastatic bladder cancer in patients who are not eligible for cisplatin-containing therapy, and whose tumors express PD-L1, as determined by an FDA-approved test
  
  Treatment of patients who are not eligible for any platinum-containing chemotherapy, regardless of PD-L1 status
Patient support services
• Genentech Oncology Co-pay Assistance Program
  855-692-6729
  
  Genentech Patient Foundation
  888-941-3331

Drug name (generic name)
• Trodelvy (sacituzumab govitecan-hziy) Injection
Drug company
• Gilead
Indication
• Treatment of adults with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a PD-1 or PD-L1 inhibitor
Patient support services
• Trodelvy Savings Program
  844-876-3358
  
  Gilead Patient Assistance Program
  844-876-3358